Home > Haematology > ASH 2020 > COVID-19 > More complicated course of COVID-19 in leukaemia patients

More complicated course of COVID-19 in leukaemia patients

Presented By
Dr Susanne Ghandili, University Medical Center Hamburg-Eppendorf, Germany
Conference
ASH 2020
SARS-CoV-2 infection has a more complicated course in leukaemia patients than in the general population and is accompanied by high viral titres in swaps and viraemia. Recent data suggests that reduced intensity therapy is warranted, especially in patients with acute myeloid leukaemia (AML) [1]. Dr Susanne Ghandili (University Medical Center Hamburg-Eppendorf, Germany) presented a series of 12 patients with acute leukaemia (median age 60 years, 25% women) and concomitant SARS-CoV-2 infection. Included were patients with newly diagnosed AML (n=3) or acute lymphoblastic leukaemia/lymphoblastic lymphoma (ALL/LBL; n=1) and patients who were already under leukaemia-specific treatment (AML n=5; ALL n=3). Patients with leukaemia had a 7-fold higher rate of severe and critical courses compared with the general population. Three patients (25%) had mild or moderate courses of COVID-19 and 9 patients (75%) had severe and critical courses, inclu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on